Advertisement

Comment to: Baloxavir efficacy in North American Adults

Published:January 15, 2020DOI:https://doi.org/10.1016/j.ejim.2019.11.005
      We write in response to several assertions stated in this letter.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de Haas E.C.
        • Luijendijk H.J.
        Baloxavir for influenza: enrichment obscured lack of effect in North-American adults.
        Eur J Intern Med. 2019; 62 (Epub 2019 Mar 8): e8-e9https://doi.org/10.1016/j.ejim.2018.12.002
        • Hayden F.G.
        • Sugaya N.
        • Hirotsu N.
        • Lee N.
        • de Jong M.D.
        • Hurt A.C.
        • Ishida T.
        • Sekino H.
        • Yamada K.
        • Portsmouth S.
        • Kawaguchi K.
        • Shishido T.
        • Arai M.
        • Tsuchiya K.
        • Uehara T.
        • Watanabe A.
        • Baloxavir Marboxil Investigators Group
        Baloxavir marboxil for uncomplicated influenza in adults and adolescents.
        N Engl J Med. 2018 Sep 6; 379: 913-923https://doi.org/10.1056/NEJMoa1716197
        • Kawaguchi K.
        • Portsmouth S.
        • Shishido T.
        • Uehara T.
        • Hayden F.G.
        Exploring clinical and antiviral efficacy of baloxavir marboxil in a phase 3, randomized, double-blind, placebo- and active-controlled study of otherwise healthy adults/adolescents in seasonal influenza: impact on regional participants, treatment time and influenza type B virus infection (CAPSTONE-1 study); IDWeek.
        2018 (Abstract 1645)
        • Ison M.G.
        • Portsmouth S.
        • Yoshida Y.
        • Shishido T.
        • Hayden F.
        • Uehara T.
        LB16. phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 Study).
        Open Forum Infect Dis. 2018; 5 (Published 2018 Nov 26): S764-S765https://doi.org/10.1093/ofid/ofy229.2190
        • Xie J.
        • Liu C.
        Adjusted Kaplan–Meier estimator and log-rank test with inverse probability of treatment weighting for survival data.
        Stat Med. 2005; 24: 3089-3110https://doi.org/10.1002/sim.2174
        • Monto A.S.
        • Gravenstein S.
        • Elliott M.
        • Colopy M.
        • Schweinle J.
        Clinical signs and symptoms predicting influenza infection.
        Arch Intern Med. 2000; 160: 3243-3247

      Linked Article

      • Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults
        European Journal of Internal MedicineVol. 62
        • Preview
          The FDA recently approved the use of baloxavir marboxil (baloxavir) in patients aged 12–64 years with uncomplicated influenza [1]. The effectiveness of baloxavir had been tested in one phase III trial named CAPSTONE-1 [2]. It consisted of two subtrials: one subtrial compared baloxavir (40 mg once) with placebo and oseltamivir in adult patients, and the other baloxavir with placebo in adolescent patients (total n = 1436). The trial was performed in Japan, the United States, and Canada. In the reported primary efficacy analysis, baloxavir reduced the time to alleviation of flu symptoms with 26.5 hours compared to placebo.
        • Full-Text
        • PDF